Search Results - "MOEHLER, M"

Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300 by Bang, Y.-J, Ruiz, E.Yañez, Van Cutsem, E., Lee, K.-W, Wyrwicz, L., Schenker, M., Alsina, M., Ryu, M.-H, Chung, H.-C, Evesque, L., Al-Batran, S.-E, Park, S.H., Lichinitser, M., Boku, N., Moehler, M.H., Hong, J., Xiong, H., Hallwachs, R., Conti, I., Taieb, J.

“…There currently are no internationally recognised treatment guidelines for patients with advanced gastric cancer/gastro-oesophageal junction cancer (GC/GEJC)…”
Get full text

Gender medicine and oncology: report and consensus of an ESMO workshop by Wagner, A.D., Oertelt-Prigione, S., Adjei, A., Buclin, T., Cristina, V., Csajka, C., Coukos, G., Dafni, U., Dotto, G.-P., Ducreux, M., Fellay, J., Haanen, J., Hocquelet, A., Klinge, I., Lemmens, V., Letsch, A., Mauer, M., Moehler, M., Peters, S., Özdemir, B.C.

“…The importance of sex and gender as modulators of disease biology and treatment outcomes is well known in other disciplines of medicine, such as cardiology,…”
Get full text

Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial by Stintzing, S., Wirapati, P., Lenz, H.-J., Neureiter, D., Fischer von Weikersthal, L., Decker, T., Kiani, A., Kaiser, F., Al-Batran, S., Heintges, T., Lerchenmüller, C., Kahl, C., Seipelt, G., Kullmann, F., Moehler, M., Scheithauer, W., Held, S., Modest, D.P., Jung, A., Kirchner, T., Aderka, D., Tejpar, S., Heinemann, V.

“…FIRE-3 compared first-line therapy with FOLFIRI plus either cetuximab or bevacizumab in 592 KRAS exon 2 wild-type metastatic colorectal cancer (mCRC) patients…”
Get full text

Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study by Stintzing, S, Miller-Phillips, L, Modest, D.P, Fischer von Weikersthal, L, Decker, T, Kiani, A, Vehling-Kaiser, U, Al-Batran, S.-E, Heintges, T, Kahl, C, Seipelt, G, Kullmann, F, Stauch, M, Scheithauer, W, Held, S, Moehler, M, Jagenburg, A, Kirchner, T, Jung, A, Heinemann, V

“…Abstract Background RAS and BRAF mutations have been identified as negative prognostic factors in metastatic colorectal cancer. Efficacy of 5-fluorouracil,…”
Get full text

Prognostic factors for progression-free and overall survival in advanced biliary tract cancer by Bridgewater, J., Lopes, A., Wasan, H., Malka, D., Jensen, L., Okusaka, T., Knox, J., Wagner, D., Cunningham, D., Shannon, J., Goldstein, D., Moehler, M., Bekaii-Saab, T., McNamara, M.G., Valle, J.W.

“…Biliary tract cancer is an uncommon cancer with a poor outcome. We assembled data from the National Cancer Research Institute (UK) ABC-02 study and 10…”
Get full text

Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER) by Moehler, M., Maderer, A., Thuss-Patience, P.C., Brenner, B., Meiler, J., Ettrich, T.J., Hofheinz, R.-D., Al-Batran, S.E., Vogel, A., Mueller, L., Lutz, M.P., Lordick, F., Alsina, M., Borchert, K., Greil, R., Eisterer, W., Schad, A., Slotta-Huspenina, J., Van Cutsem, E., Lorenzen, S.

“…Palliative chemotherapy of advanced oesophageal squamous cell cancer (ESCC) consists of cisplatin/5-fluorouracil (CF) to target epidermal growth factor…”
Get full text

Prognostic Significance of Focal Lesions in Whole-Body Magnetic Resonance Imaging in Patients With Asymptomatic Multiple Myeloma by HILLENGASS, Jens, FECHTNER, Kerstin, HO, Anthony D, KAUCZOR, Hans-Ulrich, DELORME, Stefan, GOLDSCHMIDT, Hartmut, WEBER, Marc-André, BÄUERLE, Tobias, AYYAZ, Sofia, HEISS, Christiane, HIELSCHER, Thomas, MOEHLER, Thomas M, EGERER, Gerlinde, NEBEN, Kai

“…With whole-body magnetic resonance imaging (wb-MRI), almost the whole bone marrow compartment can be examined in patients with monoclonal plasma cell disease…”
Get full text

Cetuximab plus cisplatin–5-fluorouracil versus cisplatin–5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie by Lorenzen, S., Schuster, T., Porschen, R., Al-Batran, S.-E., Hofheinz, R., Thuss-Patience, P., Moehler, M., Grabowski, P., Arnold, D., Greten, T., Müller, L., Röthling, N., Peschel, C., Langer, R., Lordick, F.

“…This study assessed the activity of the mAb cetuximab in combination with cisplatin and 5-fluorouracil (5-FU) in advanced esophageal squamous cell carcinoma…”
Get full text

Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer by Harder, J, Ihorst, G, Heinemann, V, Hofheinz, R, Moehler, M, Buechler, P, Kloeppel, G, Röcken, C, Bitzer, M, Boeck, S, Endlicher, E, Reinacher-Schick, A, Schmoor, C, Geissler, M

“…Background: New therapeutic options for metastatic pancreatic cancer are urgently needed. In pancreatic cancer, overexpression of the epidermal growth factor…”
Get full text

Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: A double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme by Moehler, M, Maderer, A, Schimanski, C, Kanzler, S, Denzer, U, Kolligs, F.T, Ebert, M.P, Distelrath, A, Geissler, M, Trojan, J, Schütz, M, Berie, L, Sauvigny, C, Lammert, F, Lohse, A, Dollinger, M.M, Lindig, U, Duerr, E.M, Lubomierski, N, Zimmermann, S, Wachtlin, D, Kaiser, A.-K, Schadmand-Fischer, S, Galle, P.R, Woerns, M

“…Abstract Background Since sorafenib has shown activity in different tumour types and gemcitabine regimens improved the outcome for biliary tract cancer (BTC)…”
Get full text

Standardized and quality-assured predictive PD-L1 testing in the upper gastrointestinal tract by Baretton, Gustavo B., Lordick, Florian, Gaiser, T., Hofheinz, R., Horst, D., Lorenzen, S., Moehler, M., Röcken, C., Schirmacher, P., Stahl, M., Thuss-Patience, P., Tiemann, K.

“…As a result of the high approval dynamics and the growing number of immuno-oncological concepts, the complexity of treatment decisions and control in the area…”
Get full text

Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study by Moehler, M., Mueller, A., Trarbach, T., Lordick, F., Seufferlein, T., Kubicka, S., Geißler, M., Schwarz, S., Galle, P.R., Kanzler, S.

“…Cetuximab plus irinotecan/folinic acid/5-fluorouracil (5-FU) (IF) was evaluated as first-line treatment of patients with advanced gastric cancer and…”
Get full text

Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer by Trarbach, T, Moehler, M, Heinemann, V, Köhne, C-H, Przyborek, M, Schulz, C, Sneller, V, Gallant, G, Kanzler, S

“…Background: Recombinant tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) induces tumour-selective apoptosis in various pre-clinical models by…”
Get full text

Relation of cetuximab-induced skin toxicity and early tumor shrinkage in metastatic colorectal cancer patients: results of the randomized phase 3 trial FIRE-3 (AIO KRK0306) by Holch, J.W., Held, S., Stintzing, S., Fischer von Weikersthal, L., Decker, T., Kiani, A., Kaiser, F., Heintges, T., Kahl, C., Kullmann, F., Scheithauer, W., Moehler, M., von Einem, J.C., Michl, M., Heinemann, V.

“…Cetuximab-induced skin toxicity (Cet-ST) is positively associated with outcome in metastatic colorectal cancer (mCRC). Besides its predictive relevance for…”
Get full text

Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial by KROPFF, Martin, GIONGCO BAYLON, Honorata, AVET-LOISEAU, Herve, MOEHLER, Thomas M, PATTOU, Claire, LUCY, Lela, KUEENBURG, Elisabeth, GLASMACHER, Axel, ZERBIB, Robert, FACON, Thierry, HILLENGASS, Jens, ROBAK, Tadeusz, HAJEK, Roman, LIEBISCH, Peter, GORANOV, Stefan, HULIN, Cyrille, BLADE, Joan, CARAVITA, Tommaso

“…Thalidomide has potent antimyeloma activity, but no prospective, randomized controlled trial has evaluated thalidomide monotherapy in patients with…”
Get full text

Dissemination of hepatocellular carcinoma is mediated via chemokine receptor CXCR4 by SCHIMANSKI, C. C, BAHRE, R, SCHULER, M, ACHENBACH, T, JUNGINGER, T, GALLE, P. R, MOEHLER, M, GOCKEL, I, MÜLLER, A, FRERICHS, K, HÖRNER, V, TEUFEL, A, SIMIANTONAKI, N, BIESTERFELD, S, WEHLER, T

“…In different tumour entities, expression of the chemokine receptor 4 (CXCR4) has been linked to tumour dissemination and poor prognosis. Therefore, we…”
Get full text

Mismatch repair deficiency, chemotherapy and survival for resectable gastric cancer: an observational study from the German staR cohort and a meta-analysis by Stolze, T., Franke, S., Haybaeck, J., Moehler, M., Grimminger, P. P., Lang, H., Roth, W., Gockel, I., Kreuser, N., Bläker, H., Wittekind, C., Lordick, F., Vieth, M., Veits, L., Waidmann, O., Lingohr, P., Peitz, U., Schildberg, C., Kruschewski, M., Vassos, N., Goni, E., Bruns, C. J., Ridwelski, K., Wolff, S., Lippert, H., Schumacher, J., Malfertheiner, P., Venerito, M.

“…Purpose In a post hoc analysis of the MAGIC trial, patients with curatively resected gastric cancer (GC) and mismatch repair (MMR) deficiency (MMRd) had better…”
Get full text

LBA6_PR Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): First results of the CheckMate 649 study by Moehler, M., Shitara, K., Garrido, M., Salman, P., Shen, L., Wyrwicz, L., Yamaguchi, K., Skoczylas, T., Campos Bragagnoli, A., Liu, T., Schenker, M., Yanez, P., Tehfe, M., Poulart, V., Cullen, D., Lei, M., Kondo, K., Li, M., Ajani, J.A., Janjigian, Y.Y.

Get full text

Advances in the management of hepatobiliary and pancreatic malignancies: highlights from the ESMO Annual Meeting 2023 by the EORTC GI Tract Cancer Group by Fulgenzi, C., Garajová, I., Moehler, M., Lutz, M.P., Smyth, E., Rimassa, L., Neuzillet, C., Lamarca, A.

Get full text

An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer by Moehler, M, Mueller, A, Hartmann, J.T, Ebert, M.P, Al-Batran, S.E, Reimer, P, Weihrauch, M, Lordick, F, Trarbach, T, Biesterfeld, S, Kabisch, M, Wachtlin, D, Galle, P.R

“…Abstract Background Sunitinib monotherapy in pretreated patients with advanced gastric cancer (AGC) was investigated. Preplanned analyses of tumour biomarkers…”
Get full text